On June 30, Insilico Medicine fell 11.12% in regular trading, trading at 38.08 HKD/share, with turnover of HKD 889 million.

On the news front, June 30 marked the official expiry date of the company's massive lock-up shares. Although the company announced that its CEO and Chief Scientific Officer voluntarily extended their personal share lock-up periods by six months to June 29 next year, the overall unlock scale remained substantial, leading to significant market selling pressure.

The stock had accumulated gains of nearly 50% since mid-June, driven by catalysts including a USD 2.5 billion AI drug discovery collaboration with SK Biopharmaceuticals and the upcoming Phase III clinical trial of Rentosertib. Heavy short-term profit-taking combined with the lock-up expiry date created resonant downward pressure. On the fundamental side, the company reported revenue declining 34.48% year-over-year with a net loss of USD 352 million, with no profitability inflection point in sight. Ernst and Young previously noted that HK stocks will face a new wave of semi-new stock unlocks in the second half of the year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)